Arrowhead Stock Fails to Meet Nasdaq Minimum Bid Requirement | GenomeWeb

Arrowhead Research, the parent firm of Calando Pharmaceuticals, said last week that it has received notice from the Nasdaq Stock Market that it does not comply with the exchange's $1 minimum bid requirement for continued listing.

The company said it has been given 180 days, until March 15, 2010, to regain compliance by maintaining a minimum closing bid price of $1 per share for 10 consecutive business days. If it does not regain compliance, Arrowhead's stock will be subjected to delisting, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.